Immunodeficiency 64 (IMD64 / RASGRP1 Deficiency): Comprehensive Disease Characteristics Report

Summary

Immunodeficiency 64 (IMD64; OMIM #618534; MONDO:0030926) is an ultra-rare autosomal-recessive combined immunodeficiency with immune dysregulation caused by biallelic loss-of-function (LOF) mutations in RASGRP1 (RAS guanyl-releasing protein 1; HGNC:9866; gene locus 15q14). RASGRP1 is a calcium- and diacylglycerol (DAG)-regulated RAS guanine-nucleotide exchange factor (RasGEF) that couples the T-cell receptor (TCR) — and other antigen receptors — to the RAS–RAF–MEK–ERK/MAPK signaling cascade. In the resting state the protein is held in an autoinhibited conformation; TCR engagement generates Ca²⁺ and DAG signals that relieve autoinhibition and switch on RAS. When both alleles are non-functional, this switch fails: thymocyte selection, lymphocyte proliferation, activation and motility, and natural-killer (NK)-cell cytotoxicity are all impaired, and — critically — cytotoxic CD8⁺ T cells cannot control Epstein–Barr-virus (EBV)-infected B cells.

Clinically, IMD64 presents in childhood with recurrent/severe infections (reported in 100% of cases), non-malignant lymphoproliferation (~87%), autoimmunity, and a strong predisposition to EBV-driven B-cell lymphoproliferative disease and lymphoma (both Hodgkin and non-Hodgkin). Autoimmune manifestations range from cytopenias (notably autoimmune hemolytic anemia) to an emerging, potentially fatal vasculopathy. The disease is defined at the disease level from aggregated case reports and small cohorts (~15 reported patients worldwide), not from large EHR datasets. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy; conservative management carries high mortality. Mechanism-based experimental options — most notably lenalidomide, which restores RhoA activity and reverses migration/activation defects in patient lymphocytes — have been reported.

This report synthesizes six confirmed findings and 28 reviewed papers into a full disease knowledge-base entry, organized by the 15 requested sections. Where information is unavailable or not applicable for this ultra-rare monogenic disorder (e.g., cancer-style survival curves, veterinary natural disease), this is stated explicitly.

Key Findings

Finding 1 — IMD64 is caused by biallelic loss-of-function RASGRP1 mutations that impair RAS–MAPK/ERK signaling

Homozygosity mapping plus exome sequencing in a consanguineous family identified a biallelic stop-gain variant in RASGRP1 that segregated perfectly with disease. Functionally, RASGRP1 deficiency reduced phosphorylation of ERK in both T and B cells, and this defect was rescued by re-expression of wild-type RASGRP1, establishing causality and the molecular mechanism (Salzer et al., 2016). This was independently confirmed by Somekh et al. (2018), who identified two additional novel LOF mutations and demonstrated, using immunoblotting and active-RAS pull-down assays, perturbed ERK1/2 signaling and reduced RAS-GTPase activity in a Jurkat model.

"we used homozygosity mapping and exome sequencing to identify a biallelic stop-gain variant in RASGRP1. This variant segregated perfectly with the disease" — PMID: 27776107

"RASGRP1 deficiency was associated in T cells and B cells with decreased phosphorylation of the extracellular-signal-regulated serine kinase ERK, which was restored following expression of wild-type RASGRP1" — PMID: 27776107

"Genetic screening identified two novel loss-of-function mutations in RASGRP1. Immunoblotting and active Ras pull-down assays confirmed perturbed ERK1/2 signaling and reduced Ras-GTPase activity" — PMID: 30030704

Interpretation: The genetic lesion is a bona-fide autosomal-recessive LOF defect, and the downstream consequence — collapse of TCR→RAS→ERK signaling — is the proximate biochemical cause of the immune phenotype.

Finding 2 — RASGRP1 deficiency causes EBV-driven lymphoproliferation and lymphoma via defective cytotoxic T-cell control of infected B cells

Patient T cells show severe activation defects that result in uncontrolled EBV-induced B-cell proliferation (Mansour et al., 2023). Somekh et al. (2018) described patients with immunodeficiency and EBV-associated lymphoproliferative disease and susceptibility to EBV-induced B-cell malignancies. Mechanistically, Latour & Fischer (2019) group RASGRP1 with MAGT1 and ITK as genes whose mutation causes defective expansion of EBV-specific CD8⁺ T cells and impaired elimination of proliferating EBV-infected B cells.

"T cells from the patient showed severe activation defects resulting in uncontrolled Epstein-Bar Virus-induced B cell proliferation" — PMID: 37898412

"the defective expansion of EBV-specific CD8 T cells results from mutations in genes involved in T-cell activation (such as RASGRP1, MAGT1, and ITK)" — PMID: 31402499

"RASGRP1 deficiency is associated with life-threatening immune dysregulation, severe autoimmune manifestations, and susceptibility to EBV-induced B cell malignancies" — PMID: 30030704

Interpretation: EBV susceptibility is not incidental; it is a direct, mechanistically predictable consequence of impaired TCR-driven CD8⁺ effector expansion. This places IMD64 firmly within the family of inborn errors of immunity predisposing to EBV lymphoproliferation (alongside XLP1/SH2D1A, XLP2/XIAP, ITK, MAGT1, CD27, CD70, CTPS1, CORO1A).

Finding 3 — RASGRP1 links TCR signaling to cytoskeletal dynamics via DYNLL1; the NK-cytotoxicity defect is reversible by lenalidomide

Beyond ERK, RASGRP1 deficiency causes defective proliferation, activation and motility of T and B cells, and impaired NK-cell cytotoxicity with defective granule convergence and actin accumulation. Interaction proteomics identified the dynein light chain DYNLL1 as a RASGRP1 interactor, linking RASGRP1 to cytoskeletal dynamics. Deficient cells showed decreased RhoA GTPase activation, and treatment with lenalidomide increased RhoA activity and reversed the migration and activation defects (Salzer et al., 2016).

"RASGRP1-deficient natural killer (NK) cells exhibited impaired cytotoxicity with defective granule convergence and actin accumulation. Interaction proteomics identified the dynein light chain DYNLL1 as interacting with RASGRP1, which links RASGRP1 to cytoskeletal dynamics" — PMID: 27776107

"Treatment with lenalidomide increased RhoA activity and reversed the migration and activation defects of RASGRP1-deficient lymphocytes" — PMID: 27776107

Interpretation: RASGRP1 has a RAS-ERK–independent, cytoskeletal arm (via DYNLL1/RhoA) that explains the NK immune-synapse and lymphocyte-motility defects. The lenalidomide rescue provides a rational, mechanism-based bridging therapy.

Finding 4 — Across ~15 reported patients, infections (100%) and lymphoproliferation (87%) predominate; vasculopathy is an emerging fatal phenotype and HSCT is the only cure

A 2026 review by Ashari et al. compiled 14 previously reported cases plus one new patient (a 5-year-old male with a novel homozygous splice-donor RASGRP1 mutation). Across this aggregated cohort, infections occurred in 100% and lymphoproliferation in 87% of cases; severe vasculopathy and fatal autoimmune hemolytic anemia are highlighted as emerging life-threatening phenotypes. HSCT remains the only curative therapy.

"A review of 14 previously reported cases (plus current case) confirms that while infections (100%) and lymphoproliferation (87%) are common, vascular autoimmunity is an emerging life-threatening phenotype. Hematopoietic stem cell transplantation remains the only curative therapy, as conservative management carries high mortality." — PMID: 42253627

Interpretation: This provides the best available disease-level quantification of penetrant phenotypes and prognosis, and flags autoimmune vasculopathy as an underrecognized driver of mortality.

Finding 5 — RASGRP1 is a calcium- and DAG-regulated RAS exchange factor held in an autoinhibited state; truncating mutations abolish this catalytic machinery

A crystal structure of a RasGRP1 fragment (Iwig et al., 2013) revealed that the RAS-binding (catalytic REM/CDC25) site is blocked by an interdomain linker and the membrane-interaction surface is hidden within a dimerization interface stabilized by the C-terminal oligomerization domain. NMR showed that Ca²⁺ binding to the EF-hand regulatory module drives conformational changes incompatible with the inactive assembly, so RasGRP1 is maintained inactive but "poised for activation by calcium and membrane-localization signals."

"We present a crystal structure of a fragment of RasGRP1 in which the Ras-binding site is blocked by an interdomain linker and the membrane-interaction surface of RasGRP1 is hidden within a dimerization interface that may be stabilized by the C-terminal oligomerization domain." — PMID: 23908768

"NMR data demonstrate that calcium binding to the regulatory module generates substantial conformational changes that are incompatible with the inactive assembly. These features allow RasGRP1 to be maintained in an inactive state that is poised for activation by calcium and membrane-localization signals." — PMID: 23908768

Interpretation: The structure explains why truncating/LOF mutations are catastrophic: they remove the catalytic and/or regulatory modules needed to convert the Ca²⁺/DAG signal into RAS-GTP loading, producing complete loss of exchange activity.

Finding 6 — Common RASGRP1 regulatory variants are autoimmunity susceptibility loci, distinct from the monogenic biallelic-null immunodeficiency

GWAS/immunochip studies associate common RASGRP1 variants with multiple autoimmune diseases: East Asian SLE (Sun et al., 2016), rheumatoid arthritis in Europeans (2016), Hashimoto's thyroiditis / TPOAb (rs7171171 near RASGRP1, OR 1.4), and IgA nephropathy. These are population-level susceptibility alleles that alter RASGRP1 expression/dosage — mechanistically distinct from the rare biallelic LOF alleles that cause IMD64.

"followed by DEF6, IL12B, TCF7, TERT, CD226, PCNXL3, RASGRP1, SYNGR1 and SIGLEC6" — PMID: 26808113

"IL6R, BACH2, RASGRP1, TLE3, and IKZF3 are replicated for the first time in an independent European population" — PMID: 26939566

"rs7171171 near RASGRP1 gene (p = 0.0356, OR = 1.4, CI = 1.02-1.92)" — PMID: 27268232

Interpretation: RASGRP1 exhibits an allelic spectrum: partial/dosage perturbation → polygenic autoimmunity; complete biallelic loss → monogenic combined immunodeficiency (IMD64). This dosage sensitivity underscores RASGRP1's central role in immune homeostasis.

Detailed Section-by-Section Report

1. Disease Information

• Overview: IMD64 is an autosomal-recessive combined immunodeficiency with immune dysregulation, characterized by defective TCR→RAS→ERK signaling, recurrent infections, lymphoproliferation, autoimmunity, and EBV-associated lymphoma.
• Key identifiers: OMIM #618534 ("Immunodeficiency 64 with lymphoproliferation"); MONDO:0030926; gene RASGRP1 (HGNC:9866; NCBI Gene 10125; OMIM 603962). Orphanet does not have a widely used dedicated ORPHAcode distinct from the RASGRP1-deficiency entry; ICD-11 best maps to 4A00.x* (Primary immunodeficiencies) / immune dysregulation category; MeSH lacks a specific term (falls under "Primary Immunodeficiency Diseases," D000081207; "Lymphoproliferative Disorders," D008232).
• Synonyms / alternative names: "Immunodeficiency 64 with lymphoproliferation"; "RASGRP1 deficiency"; "RASGRP1-related combined immunodeficiency."
• Information source: Aggregated disease-level knowledge derived from individual case reports and small case series (~15 patients), not from large-scale EHR/registry data.

2. Etiology

• Primary cause: Genetic — biallelic loss-of-function mutations in RASGRP1 (Finding 1). No environmental or infectious cause initiates the disease, though EBV acts as a critical downstream trigger of lymphoproliferation/lymphoma in the setting of the genetic defect (Finding 2).
• Genetic risk factors: The causal variants are private/rare biallelic RASGRP1 LOF alleles (stop-gain, splice-site, frameshift). Consanguinity is a major risk factor, as most reported families are consanguineous with homozygous variants (Findings 1, 4). Common RASGRP1 regulatory variants are not a cause of IMD64 but are independent autoimmunity susceptibility alleles (Finding 6).
• Environmental risk factors: EBV exposure (near-universal in humans) is the key environmental cofactor converting the immunodeficiency into life-threatening lymphoproliferation.
• Protective factors: None established genetically. Practically, EBV surveillance and avoidance of unnecessary immunosuppression may reduce complications; no protective alleles are known.
• Gene–environment interaction: The central GxE interaction is RASGRP1 LOF × EBV infection → uncontrolled B-cell proliferation and lymphoma (Findings 2, 4).

3. Phenotypes

• Progression: Generally progressive/episodic, punctuated by infection and autoimmune flares; lymphoma is a life-threatening event.
• Quality-of-life impact: Substantial — recurrent hospitalization for infection, immunosuppression, chemotherapy, and transplant; disease-specific QoL instruments (EQ-5D/SF-36) have not been reported for this ultra-rare disorder.

4. Genetic / Molecular Information

• Causal gene: RASGRP1 (HGNC:9866; NCBI Gene 10125; OMIM *603962; Ensembl ENSG00000172575; 15q14; UniProt O95267).
• Pathogenic variants: Reported variants are biallelic LOF: stop-gain/nonsense (Salzer 2016), splice-donor (Ashari 2026), frameshift, and other LOF alleles (Somekh 2018). Classification per ACMG/AMP is pathogenic/likely pathogenic for these truncating and splice variants (PVS1-supporting, given LOF is the established disease mechanism).
• Variant type/class: Nonsense, splice-site, frameshift (loss-of-function); the disease requires homozygous or compound-heterozygous LOF.
• Allele frequency: Causal alleles are extremely rare/private (absent or ultra-rare in gnomAD), consistent with recessive, often consanguineous inheritance.
• Somatic vs germline: Germline (constitutional). Secondary lymphomas may acquire somatic changes, but the primary lesion is germline.
• Functional consequence: Loss of function — abolition of RAS-GEF catalytic activity and Ca²⁺/DAG-regulated activation (Findings 1, 5).
• Modifier genes: Not formally defined; disease severity may be modulated by EBV status and other immune genes, but no specific modifiers proven.
• Epigenetic information: RASGRP1 expression is transcriptionally regulated (e.g., Nurr1 binds a RasGRP1 intron; PMID: 32612143), but disease-specific epigenetic changes in IMD64 are not established.
• Chromosomal abnormalities: None characteristic; IMD64 is a single-gene disorder, not a copy-number/aneuploidy syndrome.

5. Environmental Information

• Environmental factors: No toxic/occupational/radiation exposures cause IMD64.
• Lifestyle factors: Not applicable as causal factors.
• Infectious agents: Epstein–Barr virus (EBV; HHV-4; NCBI Taxon 10376) is the pivotal infectious trigger of lymphoproliferation and lymphoma (Findings 2, 4). Patients are also generally susceptible to recurrent bacterial and other viral infections due to combined immunodeficiency.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Biallelic RASGRP1 LOF mutation
        │  (loss of Ca2+/DAG-regulated RasGEF; catalytic/regulatory modules abolished — Iwig 2013)
        ▼
Failure to load RAS-GTP after TCR/pre-TCR engagement
        │
        ▼
Collapse of RAS → RAF → MEK → ERK1/2 (MAPK) signaling  (Salzer 2016; Somekh 2018)
        │                                   │
        ▼                                   ▼
Impaired thymocyte positive selection    Defective lymphocyte proliferation/activation
(reduced naive T-cell output)                 + RASGRP1–DYNLL1–RhoA cytoskeletal arm
        │                                   │        (impaired motility; NK granule
        ▼                                   ▼         convergence & actin — Salzer 2016)
Reduced/abnormal T-cell repertoire      Defective CD8+ effector expansion & NK cytotoxicity
        │                                   │
        └───────────────┬───────────────────┘
                        ▼
        Failure to control EBV-infected B cells
                        ▼
   Uncontrolled B-cell proliferation → lymphoproliferative disease → Hodgkin/non-Hodgkin lymphoma
                        ▼
   Concurrent loss of tolerance → autoimmunity (AIHA, cytopenias, vasculopathy)

• Molecular pathways: RAS–MAPK/ERK (KEGG hsa04014; Reactome RAF/MAP kinase cascade R-HSA-5673001); TCR signaling (KEGG hsa04660); DAG/Ca²⁺ second-messenger signaling. RASGRP1 sits upstream, converting DAG/Ca²⁺ to RAS activation; adaptors such as SKAP55 (PMID: 17658605) modulate RASGRP1.
• Cellular processes (GO suggestions): GO:0007265 (Ras protein signal transduction), GO:0000165 (MAPK cascade), GO:0050852 (T cell receptor signaling pathway), GO:0042110 (T cell activation), GO:0002323 (natural killer cell activation), GO:0030036 (actin cytoskeleton organization), GO:0007204 (positive regulation of cytosolic calcium ion concentration).
• Protein dysfunction: Loss of RAS-GEF catalytic function; truncating mutations remove REM/CDC25 catalytic and/or EF-hand/C1 regulatory modules, abolishing Ca²⁺/DAG-triggered relief of autoinhibition (Finding 5).
• Immune-system involvement: Combined immunodeficiency (impaired T, B, NK function) plus immune dysregulation/autoimmunity — a hallmark "PIRD" (primary immune regulatory disorder).
• Cell types (CL suggestions): CL:0000084 (T cell), CL:0000625 (CD8⁺ T cell), CL:0000624 (CD4⁺ T cell), CL:0000236 (B cell), CL:0000623 (natural killer cell), CL:0000813 (memory T cell).
• Molecular profiling: Functional immunology (pERK, RAS-GTP pull-down, NK cytotoxicity assays) is the main readout; no large transcriptomic/proteomic/metabolomic disease signatures have been published.

7. Anatomical Structures Affected

• Organ level: Immune/lymphoid system primarily — thymus (UBERON:0002370; impaired selection), spleen (UBERON:0002106; splenomegaly), lymph nodes (UBERON:0000029; lymphadenopathy), bone marrow (UBERON:0002371). Secondary involvement: blood vessels (UBERON:0001981; vasculopathy), kidney (UBERON:0002113; diffuse mesangial sclerosis/nephrotic syndrome reported — PMID: 39752212), and red-cell compartment (AIHA).
• Body systems: Immune/hematolymphoid (primary); cardiovascular (vasculopathy); renal (secondary).
• Tissue/cell level: Hematopoietic/lymphoid tissue; affected populations are T cells, B cells, and NK cells (CL terms above).
• Subcellular level (GO cellular component): GO:0005886 (plasma membrane; site of RAS activation), GO:0005856 (cytoskeleton; DYNLL1/RhoA arm), GO:0005768 (endosome; RasGRP1 trafficking).
• Localization/lateralization: Systemic and bilateral (lymphadenopathy, cytopenias); no characteristic lateralization.

8. Temporal Development

• Onset: Childhood-onset, typically early (some as young as infancy/toddlerhood; the new Ashari case was 5 years old). Onset pattern is chronic with acute infectious/autoimmune exacerbations.
• Progression: Progressive and episodic; lymphoproliferation may precede overt lymphoma. Vasculopathy and AIHA can be rapidly life-threatening.
• Disease course: Chronic, lifelong without curative HSCT.
• Critical periods / windows for intervention: Early diagnosis before EBV-driven lymphoma or fatal autoimmune complications; HSCT before end-organ damage offers the best outcome.

9. Inheritance and Population

• Epidemiology: Ultra-rare — approximately 15 reported patients worldwide (Finding 4). No reliable prevalence/incidence figures exist; effectively <1 per 1,000,000.
• Inheritance: Autosomal recessive (biallelic LOF).
• Penetrance / expressivity: Appears high penetrance for immunodeficiency/lymphoproliferation in biallelic-null individuals, with variable expressivity for autoimmunity, lymphoma type, and vasculopathy.
• Consanguinity: Major contributor; most reported families are consanguineous with homozygous variants.
• Founder effects / carrier frequency: No established founder alleles; carrier frequency not defined but presumed very low (rare private alleles).
• Population demographics: Cases reported from consanguineous populations (e.g., Middle Eastern, including Iranian and Turkish cohorts — PMID: 38644452, PMID: 38683392); no strong sex bias established. Common (non-causal) RASGRP1 autoimmunity alleles show population-specific frequencies (East Asian SLE, European RA — Finding 6).

10. Diagnostics

• Laboratory / immunologic tests: Lymphocyte subset quantification (variable T/B/NK abnormalities; some patients absent B cells/hypogammaglobulinemia — PMID: 38683392); functional assays — reduced TCR-induced ERK phosphorylation, reduced RAS-GTP loading, impaired T/B proliferation, and defective NK cytotoxicity (Findings 1, 3). EBV viral-load monitoring is essential.
• Biomarkers: No specific circulating biomarker; functional signaling defects and EBV load serve as surrogate markers.
• Imaging: CT/PET for lymphadenopathy/lymphoma staging; vascular imaging for vasculopathy.
• Biopsy/pathology: Lymph-node/tissue biopsy to distinguish reactive lymphoproliferation from lymphoma (Hodgkin/non-Hodgkin); renal biopsy where nephrotic syndrome occurs.
• Genetic testing (recommended, definitive): Whole-exome sequencing (WES) or whole-genome sequencing (WGS), or targeted IEI/PIRD next-generation-sequencing panels including RASGRP1 (e.g., Ion AmpliSeq Primary Immune Deficiency panel — PMID: 38644452); confirm with Sanger and segregation. Homozygosity mapping is useful in consanguineous families.
• Clinical criteria / differential diagnosis: Consider within ALPS-like / PIRD and EBV-susceptibility IEIs; differentials include XLP1 (SH2D1A), XLP2 (XIAP), ITK, MAGT1, CD27/CD70, CTPS1, CORO1A deficiencies (PMID: 34447369, PMID: 36209991). Genetic testing distinguishes them.
• Screening: Cascade genetic testing in families; carrier testing for at-risk relatives; EBV surveillance in known-affected individuals.

11. Outcome / Prognosis

• Survival/mortality: No formal survival curves exist for this ultra-rare disorder. Prognosis is guarded: conservative management carries high mortality (Finding 4). Fatal outcomes reported from lymphoma, severe infection, autoimmune hemolytic anemia, and vasculopathy. As broader context, lymphoma arising on a background of primary immunodeficiency has markedly worse survival than in immunocompetent patients (5-yr OS 41% vs 80% in a PID-malignancy cohort — PMID: 35282762).
• Morbidity/function: High — recurrent infection, chronic immunosuppression, chemotherapy, transplant-related morbidity.
• Complications: EBV lymphoma, autoimmune cytopenias, vasculopathy, nephrotic syndrome, infection.
• Recovery potential: HSCT can be curative (Finding 4); without it, chronic and often fatal.
• Prognostic factors: Early diagnosis, EBV control, absence of established lymphoma/vasculopathy at transplant, and successful HSCT engraftment.

12. Treatment

• Pharmacogenomics: Not established for IMD64.
• Gene/cell/RNA therapies: No approved gene therapy; RASGRP1 is a rational future gene-correction/HSC gene-therapy target given the hematopoietic-restricted phenotype, but this remains preclinical/theoretical.
• Treatment strategy: Genotype-driven — confirm biallelic RASGRP1 LOF, control EBV/lymphoma, manage autoimmunity, and proceed to HSCT as definitive therapy.

13. Prevention

• Primary prevention: Not possible for the genetic defect. Genetic counseling and, in consanguineous families, awareness of recessive risk. Prenatal/preimplantation genetic testing for known familial variants.
• Secondary prevention: Early molecular diagnosis (WES/panel), cascade testing, and EBV surveillance to catch lymphoproliferation early.
• Tertiary prevention: Infection prophylaxis (antimicrobials, IVIG), vaccination per IEI guidelines (avoid live vaccines where cellular immunity is compromised), and timely HSCT to prevent lethal complications.
• Counseling: Autosomal-recessive recurrence risk 25% for future offspring of carrier parents; offer carrier testing and reproductive options.

14. Other Species / Natural Disease

• Taxonomy / orthologs: RASGRP1 is conserved. Mouse Rasgrp1 (Mus musculus, NCBI Taxon 10090; NCBI Gene 19419) is the principal ortholog studied.
• Natural disease in animals: No well-characterized spontaneous RASGRP1-deficiency disease reported in companion animals or wildlife (no OMIA entry noted).
• Comparative biology: The Ras–ERK requirement for thymocyte positive selection and β-selection is evolutionarily conserved, validated extensively in mouse (see Section 15). Human and mouse share the core TCR→RASGRP1→ERK developmental mechanism.
• Zoonotic potential: Not applicable (non-transmissible genetic disorder).

15. Model Organisms

• Primary model: Mouse (Rasgrp1) knockout and knock-in models, which recapitulate key mechanistic features:
• Positive selection defect: RasGRP1 is the dominant RasGEF required at the TCR checkpoint; its deletion efficiently blocks positive selection (PMID: 22586275).
• β-selection / DN3 block & CXCR4-ERK link: RasGRP1-KO thymi show a partial DN3 developmental block and reduced proliferation; RasGRP1 is required for ERK activation downstream of CXCR4 (PMID: 23308188).
• Tail-domain knock-in: Deletion of the unique C-terminal tail impairs membrane trafficking and ERK activation and drives CD4⁺ expansion/autoantibodies with age (PMID: 22719950) — modeling the autoimmunity axis.
• γδ T cells & agonist selection: RasGRP1 is required for γδ T-cell proliferation/IL-17 and for agonist selection of TCRαβ lineages (PMID: 22623331, PMID: 28652304).
• Cellular / in vitro models: Jurkat T-leukemia cells used to demonstrate perturbed ERK1/2 and reduced RAS-GTPase activity from patient variants (PMID: 30030704); patient-derived primary lymphocytes/NK cells for functional rescue (WT re-expression, lenalidomide) (PMID: 27776107).
• Phenotype recapitulation & limitations: Mouse models faithfully reproduce the T-cell developmental and ERK-signaling defects and the autoimmunity predisposition, but do not recapitulate EBV-driven lymphoproliferation (EBV is human-restricted), a central feature of the human disease — the key limitation for modeling IMD64.
• Resources: MGI (Rasgrp1), IMPC/KOMP for engineered alleles; Cellosaurus for Jurkat.

Mechanistic Model / Interpretation

RASGRP1 is the molecular switch that translates antigen-receptor engagement into RAS-ERK activation in lymphocytes. Structural work (Finding 5) shows it is normally autoinhibited — catalytic site occluded, membrane surface buried in a dimer — until Ca²⁺ and DAG relieve autoinhibition and recruit it to the membrane to load RAS-GTP. Biallelic LOF mutations (Finding 1) destroy this switch. The consequences fan out along two arms: (i) a RAS-ERK arm that governs thymocyte selection and lymphocyte proliferation/activation, and (ii) a cytoskeletal arm via DYNLL1/RhoA that governs lymphocyte motility and NK immune-synapse/granule dynamics (Finding 3). Failure of both arms yields a combined immunodeficiency whose most dangerous manifestation is loss of CD8⁺/NK control over EBV-infected B cells (Finding 2), driving lymphoproliferation and lymphoma; concurrently, disrupted tolerance produces autoimmunity, including cytopenias and an emerging fatal vasculopathy (Finding 4).

The allelic spectrum (Finding 6) ties the rare and common ends together: partial perturbation of RASGRP1 dosage predisposes to polygenic autoimmunity (SLE, RA, thyroiditis, IgAN), while complete biallelic loss produces monogenic IMD64. This dosage sensitivity marks RASGRP1 as a rheostat of immune homeostasis.

Evidence Base

Limitations and Knowledge Gaps

• Very small evidence base (~15 patients): Frequency estimates (100% infections, 87% lymphoproliferation) come from aggregated case reports and are subject to ascertainment/publication bias.
• No formal epidemiology: True prevalence, incidence, penetrance, sex ratio, and survival statistics are unknown.
• No large omics datasets: Transcriptomic/proteomic/metabolomic disease signatures and single-cell studies are lacking.
• EBV cannot be modeled in mouse: The central lymphoproliferative phenotype is human-restricted; humanized models are needed.
• Vasculopathy mechanism undefined: The emerging fatal vasculopathy is described phenomenologically but not mechanistically dissected.
• Therapeutics largely anecdotal: Lenalidomide efficacy is based on ex-vivo/limited clinical data; HSCT outcomes lack systematic cohort analysis.
• Ontology/identifier gaps: MONDO/OMIM are established, but Orphanet/ICD-11/MeSH mappings are imprecise for this recently defined entity.

Proposed Follow-up Experiments / Actions

1. Establish an international IMD64 patient registry to obtain robust frequency, penetrance, HSCT-outcome, and survival data.
2. Systematic HSCT outcome analysis — timing, conditioning, and pre-transplant lymphoma/vasculopathy status as prognostic factors.
3. Prospective evaluation of lenalidomide (and other RhoA-restoring agents) as bridging therapy, with standardized functional endpoints (RhoA activity, migration, NK cytotoxicity).
4. Humanized/EBV-permissive models (e.g., RASGRP1-null humanized mice, patient-iPSC-derived lymphoid organoids) to model EBV lymphoproliferation and test gene correction.
5. Mechanistic study of the vasculopathy — vessel-wall immunopathology, autoantibody characterization, and cytokine profiling.
6. Autologous HSC gene therapy/gene editing feasibility studies for RASGRP1 correction, given the hematopoietic-restricted phenotype.
7. Single-cell multi-omics of patient lymphoid compartments to map cell-type-specific consequences of RAS-ERK collapse and identify biomarkers of lymphoma risk.
8. Deep-phenotyping of EBV surveillance protocols to define optimal viral-load thresholds triggering pre-emptive rituximab.